Systimmune
SystImmune is seeking a Research Associate II or Senior Research Associate to join the AIDD Protein Science Automation team in Bothell, WA. This newly created position focuses on benchmarking and operating the company’s antibody screening workflow through wet-lab experimentation in protein science and assay development. The role involves setting up and building out a new automation wet lab while generating reproducible protocols for transfer to automation.
Headquarters
Redmond, Washington, United States
Company Size
11-50 employees
Founded
2014
SystImmune is a Redmond, WA–based biopharmaceutical company developing bi‑specific and multi‑specific antibodies and antibody‑drug conjugates (ADCs) to treat cancer. Its mission is to create biologics that both directly attack tumors and activate the immune system to enhance anti‑tumor responses, using proprietary protein‑engineering and antibody‑discovery platforms. A multidisciplinary team across the U.S. and China focuses on rapid, cost‑efficient clinical development. SystImmune is a member of the Biokin Pharmaceutical group and partners with Bristol Myers Squibb and OrbiMed, and it is seeking additional collaborators to develop and commercialize its therapies worldwide.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Systimmune.
Right around the average for this role
Research Associate/ Research Scientist, Protein Science
Scripps Health
Research Assistant/Technician 3
The University of British Columbia
Associate Scientist/ Sr. Associate Scientist Antibody and Protein Engineering
Mediar Therapeutics
Purification Scientist
Eurofins
Research Associate II
Flagship Pioneering, Inc.
Scientist, Protein Expression
KOB Solutions, Inc.